These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12404570)

  • 21. Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean?
    Bedi G; Redman J
    J Psychopharmacol; 2008 Nov; 22(8):872-81. PubMed ID: 18208933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton magnetic resonance spectroscopy in ecstasy (MDMA) users.
    Daumann J; Fischermann T; Pilatus U; Thron A; Moeller-Hartmann W; Gouzoulis-Mayfrank E
    Neurosci Lett; 2004 May; 362(2):113-6. PubMed ID: 15193766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
    Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2006 Mar; 101(3):348-61. PubMed ID: 16499508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
    Reay JL; Hamilton C; Kennedy DO; Scholey AB
    J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review.
    Murphy PN; Wareing M; Fisk JE; Montgomery C
    Neuropsychobiology; 2009; 60(3-4):159-75. PubMed ID: 19893333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Information processing speed in ecstasy (MDMA) users.
    Wareing M; Fisk JE; Montgomery C; Murphy PN; Chandler MD
    Hum Psychopharmacol; 2007 Mar; 22(2):81-8. PubMed ID: 17295197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach.
    Reneman L; Booij J; Majoie CB; Van Den Brink W; Den Heeten GJ
    Hum Psychopharmacol; 2001 Dec; 16(8):579-588. PubMed ID: 12404537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug.
    Morgan CJ; Monaghan L; Curran HV
    Addiction; 2004 Nov; 99(11):1450-61. PubMed ID: 15500598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study.
    Rodgers J; Buchanan T; Scholey AB; Heffernan TM; Ling J; Parrott AC
    J Psychopharmacol; 2003 Dec; 17(4):389-96. PubMed ID: 14870950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Executive function in abstinent MDMA ('ecstasy') users.
    Zakzanis KK; Young DA
    Med Sci Monit; 2001; 7(6):1292-8. PubMed ID: 11687745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?
    Hoshi R; Pratt H; Mehta S; Bond AJ; Curran HV
    J Psychopharmacol; 2006 Mar; 20(2):291-301. PubMed ID: 16510487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences.
    Verheyden SL; Hadfield J; Calin T; Curran HV
    Psychopharmacology (Berl); 2002 Apr; 161(1):23-31. PubMed ID: 11967627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ecstasy-related deficits in the updating component of executive processes.
    Montgomery C; Fisk JE
    Hum Psychopharmacol; 2008 Aug; 23(6):495-511. PubMed ID: 18512857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acute and sub-acute effects of 'ecstasy' (MDMA) on processing of facial expressions: preliminary findings.
    Hoshi R; Bisla J; Curran HV
    Drug Alcohol Depend; 2004 Dec; 76(3):297-304. PubMed ID: 15561480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits.
    Parrott AC; Lees A; Garnham NJ; Jones M; Wesnes K
    J Psychopharmacol; 1998; 12(1):79-83. PubMed ID: 9584971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mental disorders in current and former heavy ecstasy (MDMA) users.
    Thomasius R; Petersen KU; Zapletalova P; Wartberg L; Zeichner D; Schmoldt A
    Addiction; 2005 Sep; 100(9):1310-9. PubMed ID: 16128720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visuo-spatial working memory deficits in current and former users of MDMA ('ecstasy').
    Wareing M; Fisk JE; Murphy P; Montgomery C
    Hum Psychopharmacol; 2005 Mar; 20(2):115-23. PubMed ID: 15641126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
    Parrott AC
    J Psychopharmacol; 2005 Jan; 19(1):71-83. PubMed ID: 15671132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine.
    Kuypers KP; Ramaekers JG
    J Psychopharmacol; 2005 Nov; 19(6):633-9. PubMed ID: 16272186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.